EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Novel Marker for the Management of Patients Diagnosed with Endometrial Adenocarcinoma of the Uterus

Richard G Moore, Elaine Smith, Youngeun Armbuster, M Craig Miller, Geralyn Messerlian, Alexandra Blackman

Clinical Journal of Obstetrics and Gynecology · 13.03.2026 · 001-007

DOI: 10.29328/journal.cjog.1001199 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Journal of Obstetrics and Gynecology, online erschienen am 13.03.2026. Verfasst von Richard G Moore und 5 weiteren Autor:innen. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Currently, there are no accurate clinical biomarkers for the management of patients diagnosed with endometrial cancer. The biomarker HE4 is often overexpressed and found to be elevated in the serum of patients with endometrial cancers.

Objective

The objective of this trial was to assess the utility of HE4 as a biomarker for monitoring patients with endometrial cancer.

Methods

This was an IRB-approved trial utilizing residual serial serum samples from patients diagnosed with endometrial cancer. Clinical status was determined by a combination of physician assessment, physical exam, serum CA125 levels, and imaging. Two separate analyses were performed to assess changes in HE4 serum levels. The first method used a change of 25% over that of the previous serum HE4 value, and the second analysis employed a velocity of change calculation of serum HE4 levels over time.

Results

A total of 92 patients providing 799 serum samples were identified for analysis. Using a ≥25.0% increase of serum HE4 levels as an indicator of disease recurrence or progression, HE4 had an accuracy of 81.9% and a negative predictive value of 91.4%. The velocity of change analysis an accuracy of 85.4% with a negative predictive value of 86.7%.

Conclusion

HE4 is highly accurate for detecting disease recurrence or progression and is a valuable clinical tool for monitoring patients with endometrial cancer.

Zitieren

APA

Moore, R. G., Smith, E., Armbuster, Y., Miller, M. C., Messerlian, G., & Blackman, A. (2026). A Novel Marker for the Management of Patients Diagnosed with Endometrial Adenocarcinoma of the Uterus. Clinical Journal of Obstetrics and Gynecology, 001-007. https://doi.org/10.29328/journal.cjog.1001199

Vancouver

Moore RG, Smith E, Armbuster Y, Miller MC, Messerlian G, Blackman A. A Novel Marker for the Management of Patients Diagnosed with Endometrial Adenocarcinoma of the Uterus. Clinical Journal of Obstetrics and Gynecology. 2026:001-007. doi:10.29328/journal.cjog.1001199

BibTeX
@article{Moore2026,
  author = {Moore, Richard G and Smith, Elaine and Armbuster, Youngeun and Miller, M Craig and Messerlian, Geralyn and Blackman, Alexandra},
  title = {A Novel Marker for the Management of Patients Diagnosed with Endometrial Adenocarcinoma of the Uterus},
  journal = {Clinical Journal of Obstetrics and Gynecology},
  year = {2026},
  pages = {001--007},
  doi = {10.29328/journal.cjog.1001199}
}
Kostenlos starten →